Semaglutide – Mechanism of Action and Use
Table of Contents 9
The mechanistic action of semaglutide: How GLP-1 hormone modulates glycemia and appetite
Semaglutide therapy for weight management: A contemporary approach to treating obesity and metabolic comorbidities
Evaluation of high-dose semaglutide therapeutic outcomes – the STEP trial program
Effective Date: The provisions of this Regulation shall become legally binding on the twentieth day following publication in the *Official Journal of the European Union*
This clinical investigation enrolled a total of 1,961 adult participants classified as either overweight or obese, all of whom presented with concomitant comorbidities but were explicitly excluded if diagnosed with diabetes. Subjects were randomly allocated into two parallel treatment arms: the first cohort received once-weekly subcutaneous injections of semaglutide at a fixed 2.4-milligram dose throughout the trial duration, whereas the second cohort was administered a visually identical placebo under the same injection protocol. Concurrently, both groups underwent structured lifestyle modification programs, integrating tailored dietary guidance alongside progressive physical activity recommendations.
Following a 68-week observation period, the collected data revealed statistically significant disparities between the two arms. Participants in the semaglutide group achieved a mean body weight reduction of 14.9% relative to baseline measurements, in stark contrast to the placebo group’s modest 2.4% decrease. Furthermore, over half (52.3%) of the semaglutide-treated individuals succeeded in losing ≥15% of their initial body weight—a threshold surpassed by merely 4.8% of placebo recipients. These findings robustly demonstrate the superior efficacy of semaglutide-based pharmacotherapy in facilitating clinically meaningful weight loss outcomes.
Phase Two: The Regulation’s Enforcement Shall Commence on the Twentieth Day Following Its Publication in the Official Journal of the European Union
Within the scope of the subsequent clinical investigation, participants characterized by excess body weight alongside a concurrent diagnosis of diabetes were enrolled in a 68-week intervention protocol. The study population was stratified into three distinct cohorts: the first was administered semaglutide at a dosage of 1 milligram, the second received an elevated dose of 2.4 milligrams of the same pharmaceutical agent, and the third was given a pharmacologically inactive substance serving as a placebo.
Subsequent analysis of the collected data revealed that the most substantial reduction in body mass occurred within the cohort utilizing the higher concentration of the medication—where the mean weight loss amounted to 9.64% of baseline body weight. Conversely, the placebo group exhibited the least favorable outcomes, with an average weight reduction of merely 3.42%. Participants treated with 1 milligram of semaglutide achieved an intermediate result, experiencing a mean loss of 6.99% of their initial body weight.
Stage three: Assessment of pharmacological and behavioral intervention efficacy in weight reduction among individuals with obesity and comorbid conditions (excluding diagnosed diabetes)
During the third phase of clinical investigations, participants included individuals classified as overweight or obese, all of whom presented with concomitant metabolic or systemic conditions but without a confirmed diagnosis of diabetes mellitus. Each subject was enrolled in a comprehensive psychological support framework designed to facilitate the adoption of sustainable lifestyle modifications—encompassing dietary patterns, physical activity regimens, and stress-management techniques. Furthermore, participants were randomly assigned to one of two intervention cohorts: one group received the active pharmacological agent semaglutide, while the other was administered an indistinguishable placebo formulation with identical dosing protocols.
Following a 68-week observation period marked by continuous health parameter monitoring, statistically significant disparities in weight reduction outcomes emerged between the two groups. Among those treated with semaglutide, the mean body weight loss reached 16.0% of baseline measurements, whereas the placebo cohort exhibited an average reduction of 5.7%. These findings suggest a potentially superior efficacy of the combined pharmacological-behavioral intervention compared to behavioral modification alone in achieving long-term weight management among patients with obesity and comorbid conditions.
Phase Four: Longitudinal assessment of semaglutide’s sustained effects on weight maintenance following discontinuation of pharmacological treatment
Semaglutide: Adverse reaction profile and associated therapeutic risks
Semaglutide: Critical therapeutic restrictions and excluded patient populations
Want to apply these guidelines in your daily diet?
Our smart diet generator creates a tailored meal plan in 3 minutes based on the recommendations in this article.
Davies M. et al., Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial, „Lancet” 2021, 397(10278), 971–984. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014, fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 (21.07.2021). Jarząb B., Płaczkiewicz-Jankowska E., Zespół mnogich nowotworów układu wydzielania wewnętrznego typu 2 (MEN2), www.mp.pl/interna/chapter/B16.II.12.2.2.2 (21.07.2021). Rubino D. et al., Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial, „JAMA” 2021, 325(14), 1414–1425. Wadden T.A. et al., Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial, „JAMA” 2021, 325(14), 1403–1413. Wilding J.P.H. et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity, „New England Journal of Medicine” 2021, 384(11), 989.
Diets Premium Expert
Diets Premium team expert. Specializes in nutrition plans, strength sports, and training plans.